News: Sanofi SA (SNY)

SNY on New York Consolidated

55.44USD
22 May 2013
Price Change (% chg)

$0.39 (+0.71%)
Prev Close
$55.05
Open
$55.06
Day's High
$55.86
Day's Low
$55.03
Volume
513,180
Avg. Vol
2,590,422
52-wk High
$55.86
52-wk Low
$33.03

Search Stocks
Select another date:

Fri, May 17 2013

REFILE-Sanofi says will back overhaul of Toulouse research site

(Changes 'keep' to 'back overhaul of' in headline; changes wording of paragraph 7 to remove reference to retaining site)

Continue Reading

Sanofi says will keep Toulouse research site

PARIS - Sanofi said it would overhaul rather than exit its Toulouse research site, as it seeks to break an impasse with the French government which opposed the drugmaker's reorganization plans and the loss of jobs.

Sanofi says myelofibrosis treatment study positive

PARIS, May 17 - French drugmaker Sanofi said a late-stage Phase III trial of a drug designed to treat myelofibrosis led to positive results.

Sanofi recruits patients for arthritis trials

PARIS - French drugmaker Sanofi SA said it and U.S. firm Regeneron Pharmaceuticals have started recruiting patients for two new trials of their arthritis treatment sarilumab.

FDA approves labels with lower doses for zolpidem sleep drugs

- The Food and Drug Administration approved label changes incorporating lower dosages for sleep medications containing zolpidem, a drug that can continue to affect patients' mental alertness even a day after its use.

UPDATE 1-Sanofi fined in Plavix generics dispute

* Sanofi may appeal decision, shares down 0.6 percent (Adds details, Sanofi comments, shares)

Sanofi may appeal French competition body fine

PARIS, May 14 - French drugmaker Sanofi said on Tuesday it objected to a fine by the French Competition Authority in a dispute over generic competition to its blood thinner, Plavix, and said it was considering a possible appeal.

French competition body fines Sanofi in Plavix dispute

PARIS - The French Competition Authority said on Tuesday it fined drugmaker Sanofi 40.6 million euros ($52.7 million) over what it called a smear campaign aimed at stifling generic competition to its blood thinner, Plavix.

French competition body fines Sanofi in Plavix dispute

PARIS, May 14 - The French Competition Authority said on Tuesday it fined drugmaker Sanofi 40.6 million euros ($52.7 million) over what it called a smear campaign aimed at stifling generic competition to its blood thinner, Plavix.

European shares slip from multi-year highs

* FTSEurofirst 300 down 0.1 pct, Euro STOXX 50 down 0.5 pct

Select another date:

Market Views

» More SNY Market Views

Press Releases

Search Stocks